This report outlines the process of monoclonal antibody drug patent research with the investigation of BeiGene patent portfolio related to its tislelizumab monoclonal antibody.
Merck Updates Phase 3 KEYFORM-007 Trial on Experimental Fixed-Dose Favezelimab and Pembrolizumab Combo for PD-L1 Positive Metastatic Colorectal Cancer Post-Treatment.
Recent data reveal that Almirall’s EBGLYSS® (Lebrikizumab) maintained long-term disease control for up to three years in over 80% of adults and adolescents with moderate-to-severe atopic dermatitis.
Final Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR-Positive, HER2 Low/Negative Breast Cancer from TROPION-Breast01 Phase 3 Trial Announced.